All publications

Export 14 results:
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Stirrup O, Dunn D.  2018.  Novel methodology to evaluate associations between baseline characteristics, CD4 response and viral failure on first-line ART for HIV. 22nd International Workshop on HIV and Hepatitis Observational Databases.
Stirrup O, Dunn D.  2017.  Combining ambiguous nucleotide calls with longitudinal CD4 counts and viral load measurements to derive patient-specific distributions for date of HIV seroconversion. 21st International Workshop on HIV and Hepatitis Observational Databases.
Stirrup OT, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie NE, Tostevin A, Hill T, Dunn DT, UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.  2020.  Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. HIV Med.
Stirrup OT, Dunn DT.  2018.  Estimation of delay to diagnosis and incidence in HIV using indirect evidence of infection dates.. BMC Med Res Methodol. 18(1):65.
Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT, UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.  2019.  Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV.. J Virus Erad. 5(4):204-211.
Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P.  2018.  Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.. AIDS Res Ther. 15(1):11.
Stirrup O, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie N, Dunn D, Cohort UKHIVDrug R.  2019.  Use of emtricitabine or lamivudine following detection of the M184V/I HIV-1 resistance mutation. 23rd International Workshop on HIV and Hepatitis Observational Databases.
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin CA, Nelson M, Winston A et al..  2017.  An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. J Antimicrob Chemother.
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Tostevin A, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2015.  K65R detected more frequently in HIV-1 subtype C viruses at virological failure. Conference on Retroviruses and Opportunistic Infections (CROI) 2015.
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Tostevin A, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2015.  K65R detected more frequently in HIV-1 subtype C viruses at virological failure. International HIV Drug Resistance Workshop, 2015.
Sethi G, Sabin CA, Lycett S, Ragonnet-Cronin M, Edwards SG, Fearnhill E, Dunn DT, Delpech V, Phillips AN, Pillay D et al..  2012.  Phylogenetic analysis of HIV transmission among different ethnic MSM groups in the UK. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.
Schultze A, Paredes R, Sabin CA, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM et al..  2017.  The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.. Antivir Ther.
Santoro MM, Silberstein FC, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Narciso P, Antinori AM, Palamara G et al..  2011.  Different drug-resistance development in HIV-1 infected patients failing a first-line antiretroviral therapy containing NNRTIs. IAS, 17-20 July 2011.
Santoro MM, Sabin CA, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.